Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer

Exclusion Criteria

• •1. Postoperative pathology showed Pancreatic cancer and ampullary cancer;
• •2. The former group received PD 1, PD - L1, PD patients treated L2, CTLA 4, or directly to another stimulus or common weak T cell receptors (such as CTLA - 4, 0 x40, CD137) patients;
• •3. Use of any other study medication within 4 weeks before enrollment;
• •5. People with innate or acquired immune deficiency, such as people with human immunodeficiency virus (HIV) infection;
• •6. Patients with uncontrolled cardiac clinical symptoms or diseases, such as unstable angina pectoris with NYHA II or higher heart failure, myocardial infarction within 1 year, clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;
• •7. Severe infection (e.g., requiring intravenous antibiotics, antifungal, or antiviral drugs) within 4 weeks before the first dose, or unexplained fever \>38.5°C during screening/before the first dose;
• •8. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
• •9. Live attenuated vaccine is administered within 4 weeks before the first dose or is planned for the duration of the study;
• •10. Patients with or accompanied by other systemic malignant tumors within the last 5 years (except cured basal cell carcinoma of the skin, carcinoma in situ of the cervix and ovarian cancer);
• •11. Known allergy to any of the trial drugs;
• •12. Pregnant, lactating women and subjects with reproductive capacity were unwilling to take effective contraceptive measures;
• •13. Suffering from uncontrollable psychosis; fourteen Other conditions that the investigator deemed inappropriate for inclusion. If the patient has central nervous system metastasis, serious laboratory abnormalities, accompanied by family or social factors, it will affect the safety of the subject, or the collection of data and samples.